These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 8639793)
21. Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways. Kawakami M; Kawakami K; Puri RK Int J Cancer; 2003 Jan; 103(1):45-52. PubMed ID: 12455052 [TBL] [Abstract][Full Text] [Related]
22. The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. Obiri NI; Leland P; Murata T; Debinski W; Puri RK J Immunol; 1997 Jan; 158(2):756-64. PubMed ID: 8992992 [TBL] [Abstract][Full Text] [Related]
23. Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines. Kawakami K; Kawakami M; Liu Q; Puri RK Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):230-7. PubMed ID: 16111594 [TBL] [Abstract][Full Text] [Related]
24. Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor alpha 2 chain. Kawakami K; Takeshita F; Puri RK J Biol Chem; 2001 Jul; 276(27):25114-20. PubMed ID: 11352909 [TBL] [Abstract][Full Text] [Related]
26. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli. Joshi BH; Puri RK Protein Expr Purif; 2005 Feb; 39(2):189-98. PubMed ID: 15642470 [TBL] [Abstract][Full Text] [Related]
27. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo. Leland P; Taguchi J; Husain SR; Kreitman RJ; Pastan I; Puri RK Mol Med; 2000 Mar; 6(3):165-78. PubMed ID: 10965493 [TBL] [Abstract][Full Text] [Related]
28. Cintredekin besudotox in treatment of malignant glioma. Mut M; Sherman JH; Shaffrey ME; Schiff D Expert Opin Biol Ther; 2008 Jun; 8(6):805-12. PubMed ID: 18476792 [TBL] [Abstract][Full Text] [Related]
29. Therapeutic efficacy of Cintredekin Besudotox (IL13-PE38QQR) in murine lung fibrosis is unaffected by immunity to Pseudomonas aeruginosa exotoxin A. Rosada RS; Moreira AP; Frantz FG; Puri RK; Rahman A; Standiford TJ; Zárate-Bladés CR; Silva CL; Hogaboam CM PLoS One; 2010 Jan; 5(1):e8721. PubMed ID: 20090941 [TBL] [Abstract][Full Text] [Related]
30. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy. Kawakami K; Kioi M; Liu Q; Kawakami M; Puri RK J Immunother; 2005; 28(3):193-202. PubMed ID: 15838375 [TBL] [Abstract][Full Text] [Related]
31. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy. Shimamura T; Husain SR; Puri RK Neurosurg Focus; 2006 Apr; 20(4):E11. PubMed ID: 16709016 [TBL] [Abstract][Full Text] [Related]
32. Cytotoxic activity of a recombinant fusion protein between interleukin 4 and Pseudomonas exotoxin. Ogata M; Chaudhary VK; FitzGerald DJ; Pastan I Proc Natl Acad Sci U S A; 1989 Jun; 86(11):4215-9. PubMed ID: 2657746 [TBL] [Abstract][Full Text] [Related]
33. Identification, characterization, and targeting of IL-4 receptor by IL-4-Pseudomonas exotoxin in mouse models of anaplastic thyroid cancer. Joshi BH; Suzuki A; Fujisawa T; Leland P; Varrichio F; Lababidi S; Lloyd R; Kasperbauer J; Puri RK Discov Med; 2015 Nov; 20(111):273-84. PubMed ID: 26645899 [TBL] [Abstract][Full Text] [Related]
34. Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease. Kawakami K; Kawakami M; Puri RK Mol Cancer Ther; 2004 Feb; 3(2):137-47. PubMed ID: 14985454 [TBL] [Abstract][Full Text] [Related]
36. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin. Husain SR; Gill P; Kreitman RJ; Pastan I; Puri RK Mol Med; 1997 May; 3(5):327-38. PubMed ID: 9205948 [TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-pseudomonas exotoxin fusion protein. Joshi BH; Leland P; Puri RK Croat Med J; 2003 Aug; 44(4):455-62. PubMed ID: 12950150 [TBL] [Abstract][Full Text] [Related]
38. Novel way to increase targeting specificity to a human glioblastoma-associated receptor for interleukin 13. Debinski W; Gibo DM; Puri RK Int J Cancer; 1998 May; 76(4):547-51. PubMed ID: 9590132 [TBL] [Abstract][Full Text] [Related]
39. Cytotoxic activity of an interleukin 6-Pseudomonas exotoxin fusion protein on human myeloma cells. Siegall CB; Chaudhary VK; FitzGerald DJ; Pastan I Proc Natl Acad Sci U S A; 1988 Dec; 85(24):9738-42. PubMed ID: 3264406 [TBL] [Abstract][Full Text] [Related]
40. A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin. Debinski W; Puri RK; Kreitman RJ; Pastan I J Biol Chem; 1993 Jul; 268(19):14065-70. PubMed ID: 8314773 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]